Multiple Myeloma
Key Points
Key Points
- In 2018, an estimated 30,770 new cases of multiple myeloma will be diagnosed in the United States, representing 1.8% of all new cancer cases.
- The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
- Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
- The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
...reatment
...nsplant Eligibl...
...be referred to a transplant center to de...
Chronologic age and renal function should not be...
The optimal regimen and number of...
...transplant should be offered to all transplant-...
...ts associated with stem cell toxicity,...
...mple stem cell collection (sufficient for...
...level of minimal response required to...
...lphalan is the recommended conditi...
...logous SCT should not be routinely recommende...
...elayed SCT may be used as consolidation at fir...
...neic transplant for multiple myelo...
...ation therapy is not routinely recommended but...
...omide maintenance therapy should be routinely o...
...patients intolerant of or unable to r...
...h-risk patients, maintenance therapy with...
...fficient evidence to make modifications to m...
...quality and depth of response should...
...l of initial therapy for transplant eligible pa...
...ded that depth of response be assessed with ea...
...dose CT scan has been shown to be superior to sk...
...splant Ineligib...
...t recommendations for patients with multiple...
...tment for patients with multiple myelo...
...let therapies for patients with multipl...
...ans/patients should balance the pot...
...us therapy should be offered over fixed...
...oal of initial therapy for transplant inelig...
...ponse for all patients should be assessed...
...e is insufficient evidence to support ch...
...of therapy, one should define patient spe...
...ded that patients be monitored closely with con...
...apsed Disease
...reatment for biochemically relapsed myelom...
...relapsed patients with symptoms due t...
...therapy should be administered on first relapse,...
...atment of relapsed multiple myeloma...
...s should be taken into consideration when selecti...
Autologous stem cell transplantation,...
...sk status of the patients should be asses...
...t risk assessment at the time of relapse should b...
...ther risk factors such as renal insufficiency, ag...
...ients with genetic high-risk disease a t...
...patients with renal insufficiency, drugs should...
...s with plasma cell leukemia or extra medul...
...ed response criteria should be used for respo...
All measurable parameters need to be foll...
...ll responses excluding marrow and imaging sho...
...ssessment should be performed after one cycle of...
...igure 1. Algorithm On Management of...
...Used in the Management of Patients With Mul...
...ostic Criteria for Active Multiple...
Table 3. Revised International Stag...
...parison of Select Risk Prediction Models...
...Response CriteriaHaving trouble viewing...
...Estimated Cost of Drugs for Multiple Myeloma...